<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="150315">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01143389</url>
  </required_header>
  <id_info>
    <org_study_id>2010-0243</org_study_id>
    <nct_id>NCT01143389</nct_id>
  </id_info>
  <brief_title>Corneal Crosslinking in Patients With Keratoconus and Post-Refractive Ectasia</brief_title>
  <official_title>Evaluation of Two Riboflavin Dosing Regimens for Corneal Collagen Cross-Linking in Eyes With Progressive Keratoconus or Ectasia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Price Vision Group</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Price Vision Group</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the effectiveness of using riboflavin and UV light
      to treat progressive keratoconus or post-refractive corneal ectasia.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The primary objective of this study is to evaluate two riboflavin-dosing regimens for
      corneal collagen cross-linking to slow the progressive changes in corneal curvature in eyes
      with progressive keratoconus or post-refractive ectasia.
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>May 2010</start_date>
  <completion_date type="Anticipated">May 2017</completion_date>
  <primary_completion_date type="Anticipated">May 2017</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Participant, Investigator</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in corneal curvature</measure>
    <time_frame>6 months</time_frame>
    <description>Measured by maximum keratometry (Kmax)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pachymetry</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Corrected Distance Acuity (CDA)</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Manifest Refraction</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">264</enrollment>
  <condition>Keratoconus</condition>
  <condition>Post-Refractive Ectasia</condition>
  <arm_group>
    <arm_group_label>Riboflavin 0.1% eyedrops every 5 minutes</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>The eye will be irradiated for 30 minutes with UVX light, during which time instillation of riboflavin will continue (1 drop every 5 minutes for this arm).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Riboflavin 0.1% eyedrops every 2 minutes</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>The eye will be irradiated for 30 minutes with UVX light, during which time instillation of riboflavin will continue (1 drop every 2 minutes for this arm).</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Riboflavin</intervention_name>
    <description>Riboflavin 0.1% eye drops are applied before and during irradiation of the cornea.</description>
    <arm_group_label>Riboflavin 0.1% eyedrops every 5 minutes</arm_group_label>
    <arm_group_label>Riboflavin 0.1% eyedrops every 2 minutes</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>UVX light</intervention_name>
    <description>UVX 365 nm wavelength light source is applied with continued application of riboflavin.</description>
    <arm_group_label>Riboflavin 0.1% eyedrops every 5 minutes</arm_group_label>
    <arm_group_label>Riboflavin 0.1% eyedrops every 2 minutes</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. 10 years of age or older

          2. Having documented ectasia on topography or tomography after previous refractive
             surgery OR progressive keratoconus defined as one or more of the following changes
             over a period of 36 months or less before randomization:

               1. An increase of ≥ 1.00 D in the steepest keratometry value (or sim K)

               2. An increase of ≥ 1.00 D in regular astigmatism evaluated by subjective manifest
                  refraction

               3. A myopic shift (decrease in the spherical equivalent) of ≥ 0.50 D on subjective
                  manifest refraction

               4. Documented decrease in visual acuity associated with irregular astigmatism and
                  topographic features of ectasia.

          3. Subjects with keratoconus diagnosis only:

             a. Axial topography consistent with keratoconus b. Presence of central or inferior
             steepening on the Pentacam map. c. Presence of one or more slit lamp findings
             associated with keratoconus, such as: i. Fleischer ring ii. Vogt striae iii. Corneal
             thinning iv. Corneal scarring

          4. Contact Lens Wearers Only: Removal of contact lenses for the required period of time
             prior to the screening refraction:

             Contact Lens Type Minimum Discontinuation Time Soft 3 Days Soft Extended Wear 1 Week
             Soft Toric 2 Weeks Rigid gas permeable 2 Weeks

          5. Signed written informed consent

        Exclusion Criteria:

          -  1. Any keratoconus patient over 21 years of age without evidence of progression of
             his corneal deformity.

             2. Patients with excessively thin corneas. 3. Previous ocular condition in the eyes
             to be treated that may predispose the eye for future complications, for example:

             a. History of corneal disease (e.g., herpes simplex, herpes zoster keratitis,
             recurrent erosion syndrome, corneal melt, corneal dystrophy, etc.) b. Clinically
             significant corneal scarring in the proposed treatment zone 4. A history of chemical
             injury or delayed epithelial healing in the eye(s) to be treated.

             5. A known sensitivity to treatment medications. 6. Patients with a current condition
             that, in the treating physician's opinion, would interfere with or prolong epithelial
             healing.

             7. Pregnancy (including plan to become pregnant) or lactation during the course of
             the study
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>10 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Francis W Price, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Price Vision Group</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Price Vision Group</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46260</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.pricevisiongroup.com/</url>
    <description>Price Vision Group Website</description>
  </link>
  <reference>
    <citation>Wittig-Silva C, Whiting M, Lamoureux E, Lindsay RG, Sullivan LJ, Snibson GR. A randomized controlled trial of corneal collagen cross-linking in progressive keratoconus: preliminary results. J Refract Surg. 2008 Sep;24(7):S720-5.</citation>
    <PMID>18811118</PMID>
  </reference>
  <reference>
    <citation>Raiskup-Wolf F, Hoyer A, Spoerl E, Pillunat LE. Collagen crosslinking with riboflavin and ultraviolet-A light in keratoconus: long-term results. J Cataract Refract Surg. 2008 May;34(5):796-801. doi: 10.1016/j.jcrs.2007.12.039.</citation>
    <PMID>18471635</PMID>
  </reference>
  <reference>
    <citation>Mazzotta C, Traversi C, Baiocchi S, Sergio P, Caporossi T, Caporossi A. Conservative treatment of keratoconus by riboflavin-uva-induced cross-linking of corneal collagen: qualitative investigation. Eur J Ophthalmol. 2006 Jul-Aug;16(4):530-5.</citation>
    <PMID>16952090</PMID>
  </reference>
  <reference>
    <citation>Caporossi A, Baiocchi S, Mazzotta C, Traversi C, Caporossi T. Parasurgical therapy for keratoconus by riboflavin-ultraviolet type A rays induced cross-linking of corneal collagen: preliminary refractive results in an Italian study. J Cataract Refract Surg. 2006 May;32(5):837-45.</citation>
    <PMID>16765803</PMID>
  </reference>
  <verification_date>April 2017</verification_date>
  <lastchanged_date>April 3, 2017</lastchanged_date>
  <firstreceived_date>June 11, 2010</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Keratoconus</keyword>
  <keyword>Ectasia</keyword>
  <keyword>cross linking</keyword>
  <keyword>collagen cross linking</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Keratoconus</mesh_term>
    <mesh_term>Dilatation, Pathologic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Riboflavin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
